"Jan. 29, 2013 -- Older women with heart problems may be at greater risk for mental changes that are thought to signal the beginnings of a type of dementia, a new study shows.
Called vascular dementia, it is a type of mental decline that"...
Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
DOSAGE AND ADMINISTRATION
DEFINITY® is intended for administration only after activation in the VIALMIX® apparatus. Before injection, this product must be activated and prepared according to the instructions outlined below. The VIALMIX® apparatus should be ordered from Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, MA, 01862. For customer orders call 1-800-299-3431.
DEFINITY® may be injected by either an intravenous (IV) bolus or infusion. The maximum dose is either two bolus doses or one single intravenous infusion. The safety of bolus and infusion dosing in combination or in sequence, has not been studied.
The recommended bolus dose for activated DEFINITY® is 10 microliters (microL)/kg of the activated product by intravenous bolus injection within 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (microL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement.
The recommended infusion dose for activated DEFINITY® is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute.
After baseline non-contrast echocardiography is completed, set the mechanical index for the ultrasound device at 0.8 or below [see WARNINGS AND PRECAUTIONS]. Then inject activated DEFINITY® (as described above) and begin ultrasound imaging immediately. Evaluate the activated DEFINITY® echocardiogram images in combination with the non-contrast echocardiogram images.
In a crossover trial of 64 patients randomized to both bolus and infusion, the duration of clinically useful contrast enhancement for fundamental imaging was approximately 3.4 minutes after a 10 microL/kg bolus and was approximately 7.1 minutes during the continuous infusion of 1.3 mL activated DEFINITY® in 50 mL saline at a rate of 4 mL/min.
DEFINITY® Activation, Preparation and Handling Instructions
- Allow the vial to warm to room temperature before starting the activation procedure.
- Activate DEFINITY® by shaking the vial for 45 seconds using a VIALMIX®.
Note: illustrations of this procedure are contained in the VIALMIX® Users Guide.
Do not use this drug unless it has completed a full 45 second activation cycle in the VIALMIX®. DEFINITY® will not be properly activated unless the full 45 second activation cycle is completed. Do not reactivate the vial if VIALMIX® did not complete a full 45 second cycle. Do not reactivate a successfully activated DEFINITY® vial (see step 3). Do not use a VIALMIX® that is not functioning properly. Refer to the “VIALMIX® User's Guide” for the “VIALMIX® calibration and replacement procedures” to ensure that a properly functioning VIALMIX® is used.
- Immediately after activation in the VIALMIX®, activated DEFINITY® appears as a milky white suspension and may be used immediately after activation. If the product is not used within 5 minutes of VIALMIX® activation, the microspheres should be resuspended by 10 seconds of hand agitation by inverting the vial before the product is withdrawn in a syringe. The activated DEFINITY® may be used for up to 12 hours from the time of VIALMIX®, but only after the microspheres are resuspended by hand agitation. Store the activated DEFINITY® at room temperature in the original product vial.
- Invert the vial and withdraw the activated milky white suspension using the Intellipin™ (Dispensing Pin) or 18 to 20 gauge syringe needle. Withdraw the material from the middle of the liquid in the inverted vial. Do not inject air into the DEFINITY® VIAL.
- Use the product immediately after its withdrawal from the vial; do not allow the product to stand in the syringe.
For single use only: DEFINITY® does not contain bacterial preservative. Bacterial contamination with the risk of post-administration septicemia can occur following the puncture of the elastomeric septum. It is essential to follow directions for activation of DEFINITY® carefully and to adhere to strict aseptic procedures during preparation.
Dosage Forms And Strengths
DEFINITY® is supplied as a single use 2-mL clear glass vial containing a clear liquid. Each package contains four (4) single-use vials.
Prior to activation, the headspace of each vial contains 6.52 mg/mL octafluoropropane and the clear liquid contains 0.75mg/mL of a lipid blend. After activation, each vial contains a maximum of 1.2 X 1010 perflutren lipid microspheres, and about 150 microL/mL (1.1 mg/mL) octafluoropropane [see DESCRIPTION].
DEFINITY® is supplied as a single use 2-mL clear glass vial containing clear liquid. Each package (clear plastic clamshell) contains four (4) single-use vials.
NDC (11994-011-01), vial
NDC (11994-011-04), 4 vial kit
Storage and Handling
Store between 2-8°C (36°-46°F).
FOR SINGLE USE ONLY: DEFINITY® does not contain bacterial preservative. Bacterial contamination with the risk of post-administration septicemia can occur following the puncture of the elastomeric septum. It is essential to follow directions for activation of DEFINITY® carefully and to adhere to strict aseptic procedures during preparation.
Manufacturer details: n/a. Revised: October, 2011
Last reviewed on RxList: 11/4/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Definity Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.